The discovery and development of belimumab: the anti-BLyS–lupus connection

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Cellular Competition Independent of BAFF/B Lymphocyte Stimulator Results in Low Frequency of an Autoreactive Clonotype in Mature Polyclonal B Cell Compartments

(2011) N. Nikbakht et al.   JOURNAL OF IMMUNOLOGY

B Cell and BAFF Dependence of IFN- -Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice

(2011) N. Jacob et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis

(2011) Xiaohui Zhou et al.   PLoS One

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells

(2010) Y. Iwata et al.   BLOOD

B Cell-Targeted Therapies for Systemic Lupus Erythematosus

(2010) R. John Looney   DRUGS

Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF

(2010) M. Ota et al.   JOURNAL OF IMMUNOLOGY

Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice

(2010) K. M. Haas et al.   JOURNAL OF IMMUNOLOGY

Regulatory B Cells (B10 Cells) Have a Suppressive Role in Murine Lupus: CD19 and B10 Cell Deficiency Exacerbates Systemic Autoimmunity

(2010) R. Watanabe et al.   JOURNAL OF IMMUNOLOGY

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

(2009) Manuel Ramos-Casals et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway

(2009) N. Jacob et al.   JOURNAL OF IMMUNOLOGY

The Role of IL-23/IL-17 Axis in Lupus Nephritis

(2009) Z. Zhang et al.   JOURNAL OF IMMUNOLOGY

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

(2008) E. Belnoue et al.   BLOOD

Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept

(2008) Michela Carbonatto et al.   TOXICOLOGICAL SCIENCES

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY